-
41.发明申请公开(公告)号：US20180125929A1
公开(公告)日：2018-05-10
申请号：US15639506
申请日：2017-06-30
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Jens FRITSCHE , Toni WEINSCHENK , Steffen WALTER , Peter LEWANDROWSKI , Harpreet SINGH
CPC classification number: A61K38/1709 , A61K39/0011 , A61K2039/5158 , A61K2039/572 , A61K2039/585 , A61P35/00 , C07K7/06 , C07K2319/00 , G01N33/505
Abstract: A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer. A method of treating a patient who has cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the cancer.
-
42.发明申请公开(公告)号：US20180000896A1
公开(公告)日：2018-01-04
申请号：US15639310
申请日：2017-06-30
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Jens FRITSCHE , Toni WEINSCHENK , Steffen WALTER , Peter LEWANDROWSKI , Harpreet SINGH
CPC classification number: A61K38/1709 , A61K39/0011 , A61K2039/5158 , A61K2039/572 , A61K2039/585 , A61P35/00 , C07K7/06 , C07K2319/00 , G01N33/505
Abstract: A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer. A method of treating a patient who has cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the cancer.
-
公开(公告)号：US20170320913A1
公开(公告)日：2017-11-09
申请号：US15639165
申请日：2017-06-30
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni WEINSCHENK , Steffen WALTER , Jens FRITSCHE , Colette SONG , Harpreet SINGH
CPC classification number: C07K7/08 , A61K38/1709 , A61K39/0011 , C07K7/06 , C12N5/0638 , C12N9/6491 , C12Y304/24065
Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
公开(公告)号：US20160376313A1
公开(公告)日：2016-12-29
申请号：US15226081
申请日：2016-08-02
Applicant: immatics biotechnologies GmbH
Inventor： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
CPC classification number: C07K7/06 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20160175357A1
公开(公告)日：2016-06-23
申请号：US14865278
申请日：2015-09-25
Applicant: immatics biotechnologies GmbH
Inventor： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
IPC: A61K35/17 , C12N5/0783 , C07K14/47
CPC classification number: A61K35/17 , A61K38/00 , C07K7/06 , C07K7/08 , C07K14/4748 , C12N5/0638
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
Patent Agency Ranking
46.发明申请IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC 审中-公开对几种肿瘤进行免疫治疗，如肺癌，包括NSCLC公开(公告)号：US20160168200A1
公开(公告)日：2016-06-16
申请号：US14908078
申请日：2014-08-04
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni WEINSCHENK , Steffen WALTER , Jens FRITSCHE , Colette SONG , Harpreet SINGH
CPC classification number: A61K39/0011 , A61K38/1709 , A61K45/06 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/7051 , C12N5/0638 , C12N9/6491 , C12N2502/11 , C12Y304/24065
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to more than 70 novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
Abstract translation: 本发明涉及用于免疫治疗方法的肽，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及肿瘤相关的细胞毒性T细胞（CTL）肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。 本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的70多种新型肽序列及其衍生自人类肿瘤细胞的HLA I类和HLA II类分子的变体。
-
47.发明申请公开(公告)号：US20250049886A1
公开(公告)日：2025-02-13
申请号：US18920658
申请日：2024-10-18
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens FRITSCHE , Toni WEINSCHENK , Steffen WALTER , Peter LEWANDROWSKI , Harpreet SINGH
Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
公开(公告)号：US20240182522A1
公开(公告)日：2024-06-06
申请号：US18405731
申请日：2024-01-05
Applicant: Immatics Biotechnologies GmbH
Inventor： Toni WEINSCHENK , Steffen WALTER , Jens FRITSCHE , Colette SONG , Harpreet SINGH
IPC: C07K7/08 , A61K38/17 , A61K39/00 , A61K45/06 , C07K7/06 , C07K14/725 , C12N5/0783 , C12N9/64
CPC classification number: C07K7/08 , A61K38/1709 , A61K39/0011 , A61K45/06 , C07K7/06 , C07K14/7051 , C12N5/0638 , C12N9/6491 , C12Y304/24065 , A61K2039/5158 , A61K2039/572 , C12N2502/11
Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
公开(公告)号：US20230263873A1
公开(公告)日：2023-08-24
申请号：US18178055
申请日：2023-03-03
Applicant: Immatics Biotechnologies GmbH
Inventor： Sabrina KUTTRUFF-COQUI , Toni WEINSCHENK , Jens FRITSCHE , Steffen WALTER , Norbert HILF , Oliver SCHOOR , Colette SONG , Harpreet SINGH
IPC: A61K39/00 , C07K14/47 , C07K14/705 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/74 , C07K16/28 , C12Q1/6886
CPC classification number: A61K39/0011 , C07K14/4748 , C07K14/705 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/70539 , C07K16/2833 , C12Q1/6886 , A61K2039/80 , A61K2039/5158 , A61K2039/572 , C07K2319/33 , C12Q2600/136 , C12Q2600/158 , C12Q2600/16
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20220194984A1
公开(公告)日：2022-06-23
申请号：US17691576
申请日：2022-03-10
Applicant: Immatics Biotechnologies GmbH
Inventor： Toni WEINSCHENK , Steffen WALTER , Jens FRITSCHE , Colette SONG , Harpreet SINGH
Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an WIC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
-
-
-
-
-
-
-
-
Search Results
72
records
(took 0.043 seconds)
